Production (Stage)
ProQR Therapeutics N.V.
PRQR
$1.91
$0.126.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.00% | 1.17% | 31.65% | 57.86% | 52.44% |
| Total Depreciation and Amortization | 2.48% | 9.90% | 13.23% | 14.58% | 10.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 173.92% | 205.25% | -160.10% | -136.00% | -179.36% |
| Change in Net Operating Assets | 16.68% | -127.34% | -125.48% | -129.34% | -124.85% |
| Cash from Operations | 4.93% | -272.57% | -440.61% | -1,335.94% | -2,585.56% |
| Capital Expenditure | 54.06% | -3.73% | -148.87% | -199.70% | -240.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -75.22% | -75.22% | -75.22% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 227.51% | -143.14% | -- | -- | -- |
| Cash from Investing | 202.23% | -189.90% | 651.75% | -2,155.49% | -2,454.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 46.87% | 39.83% | -54.39% | 94.23% | 93.40% |
| Issuance of Common Stock | 13,807.56% | 20,198.87% | -97.38% | -96.29% | -96.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,937.96% | 3,145.25% | -119.03% | 92.78% | 91.41% |
| Foreign Exchange rate Adjustments | -84.68% | 8.58% | 63.45% | -98.31% | -85.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.90% | 25.49% | -255.76% | -105.98% | -116.71% |